United TherapeuticsBSP:U2TH34 65 Shareholder Yield % is 10.84% as of Mar. 2026, which is 2830% above its 10-year median of 0.37. GuruFocus rates BSP:U2TH34 with a GF Score™ of 65/100 and a GF Value™ of R$97.21 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 973 Drug Manufacturers companies, United Therapeutics ranks better than 93.53% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, United Therapeutics's Shareholder Yield % was 10.84%.
United Therapeutics (BSP:U2TH34) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
United Therapeutics Shareholder Yield % Related Terms
United Therapeutics Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:U2TH34 vs VTRS, NBIX, ZTS: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
United Therapeutics (BSP:U2TH34) has a Shareholder Yield % of 10.84% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on United Therapeutics and its competitors. This is 2830% above median its historical median of 0.37. According to the industry distribution chart, United Therapeutics ranks #63 out of 973 companies in the Drug Manufacturers industry, placing it in the top 6.5%.
Is United Therapeutics' Shareholder Yield % too high?
United Therapeutics' current Shareholder Yield % of 10.84% is 2830% above median its 10-year median of 0.37. The Drug Manufacturers industry median Shareholder Yield % is 0.30. United Therapeutics' value of 10.84% is 3513.3% above this industry median. Based on the distribution chart, United Therapeutics ranks #63 out of 973 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Shareholder Yield % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #63 out of 973 companies for Shareholder Yield %. This places United Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.30. United Therapeutics' value of 10.84% is 3513.3% above this benchmark. While the company's 10-year median is 0.37 vs. the industry median of 0.30, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current Shareholder Yield % of 10.84% is 3513.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current Shareholder Yield % is 10.84%, which is 2830% above median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (BSP:U2TH34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$97.21, compared to a current price of R$137.50 — trading 41.4% above its estimated fair value. The current Shareholder Yield % is 10.84%, which is 2830% above median its 10-year median of 0.37 and 3513.3% above the Drug Manufacturers industry median of 0.30. United Therapeutics' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current Shareholder Yield % is 10.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of R$137.50 is trading 41.4% above its estimated GF Value™ of R$97.21.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for BSP:U2TH34:
Shareholder Yield %: 10.84% (2830% above median its 10-year median of 0.37)
GF Value™: R$97.21 vs. price of R$137.50 (41.4% above fair value)
Industry Position: 3513.3% above the Drug Manufacturers median (#63 of 973)
No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score
Get the complete analysis for BSP:U2TH34
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:U2TH34 has been successfully added to your 
